Results · Apr-Jun 2026
Tatva Chintan Pharma Chem Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 43% to ₹167 crore from ₹117 crore in Apr-Jun 2025.
Operating profit grew 86% to ₹32.3 crore, an operating margin of 19.3% (up 4.5 points from a year ago).
Net profit grew 140% to ₹16 crore from ₹6.7 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +25%, net profit +55%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 167.1 | 116.9 | +43% |
| Operating profit (EBITDA) | 32.3 | 17.3 | +86% |
| Operating margin | 19.3% | 14.8% | +4.5 pts |
| Net profit | 16.0 | 6.7 | +140% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.